<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032183</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0545</org_study_id>
    <secondary_id>NCI-2021-08859</secondary_id>
    <secondary_id>2021-0545</secondary_id>
    <nct_id>NCT05032183</nct_id>
  </id_info>
  <brief_title>Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma</brief_title>
  <official_title>Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib/II trial studies the effects of tagraxofusp and low-intensity chemotherapy in&#xD;
      treating patients with CD123 positive acute lymphoblastic leukemia or lymphoblastic lymphoma&#xD;
      that has come back (relapsed) or does not respond to treatment (refractory). Tagraxofusp&#xD;
      consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3 attaches to&#xD;
      IL3 receptor positive cancer cells in a targeted way and delivers DT388 to kill them.&#xD;
      Chemotherapy drugs, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving&#xD;
      tagraxofusp with chemotherapy may help control CD123 positive relapsed or refractory acute&#xD;
      lymphoblastic leukemia or lymphoblastic lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the overall response rate (complete response [CR] + CR with inadequate count&#xD;
      recovery [CRi]) of the regimen within 3 cycles.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate other clinical efficacy endpoints (CR rate, minimal residual disease [MRD]&#xD;
      negativity, duration of response [DOR], relapse-free survival [RFS] overall survival [OS]).&#xD;
&#xD;
      II. Determine the proportion of patients proceeding to allogeneic stem cell transplantation&#xD;
      (allo-SCT).&#xD;
&#xD;
      III. Determine the safety of the combination regimen.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To determine CD123 expression levels pre- and post-therapy. II. To correlate baseline&#xD;
      CD123 expression with response rates and duration of response.&#xD;
&#xD;
      III. To evaluate change in apoptotic protein expression and alterations in cellular signaling&#xD;
      pathways using cytometry by time of flight (CyTOF).&#xD;
&#xD;
      IV. To determine baseline gene expression profile in order to identify ALL subtypes and&#xD;
      correlate with clinical outcomes and response to single-agent tagraxofusp-erzs (tagraxofusp).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      TAGRAXOFUSP AND CHEMOTHERAPY PHASE:&#xD;
&#xD;
      CYCLE 1: Patients receive tagraxofusp-erzs intravenously (IV) over 15 minutes on days 1-5.&#xD;
&#xD;
      CYCLES 2 AND 4: Patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3,&#xD;
      cyclophosphamide IV over 3 hours twice daily (BID) and mesna IV on days 4-6, vincristine IV&#xD;
      over 15 minutes on days 4 and 15, dexamethasone IV over 30 minutes or orally (PO) on day 4-7&#xD;
      and 14-17, methotrexate intrathecally (IT) on day 5, and filgrastim-sndz subcutaneously (SC)&#xD;
      or pegfilgrastim SC on day 8, and cytarabine IT on day 10. Patients may receive rituximab IV&#xD;
      over 4-6 hours on days 4 and 14.&#xD;
&#xD;
      CYCLES 3 AND 5: Patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3,&#xD;
      methotrexate IV over 24 hours on day 4, cytarabine IV over 3 hours BID on days 5-6,&#xD;
      filgrastim-sndz SC or pegfilgrastim SC on day 6, methotrexate IT and cytarabine IT on day 11.&#xD;
      Patients may receive rituximab IV over 4-6 hours on days 4 and 11. Beginning about 12 hours&#xD;
      after the day 4 dose of methotrexate, patients may also receive leucovorin IV over 15&#xD;
      minutes, 4 times a day for about 8 doses.&#xD;
&#xD;
      CYCLES 6 AND 8: Patients receive cyclophosphamide IV over 3 hours BID and mesna IV on days&#xD;
      1-3, vincristine IV over 15 minutes on days 1 and 11, dexamethasone IV over 30 minutes or PO&#xD;
      on day 1-4 and 11-14, and filgrastim-sndz SC or pegfilgrastim SC on day 5.&#xD;
&#xD;
      CYCLES 7 AND 9: Patients receive methotrexate IV over 24 hours on day 1, cytarabine IV over 3&#xD;
      hours BID on days 2-3, and filgrastim-sndz SC or pegfilgrastim SC on day 4. Beginning about&#xD;
      12 hours after the day 1 dose of methotrexate, patients may receive leucovorin IV over 15&#xD;
      minutes, 4 times a day for about 8 doses.&#xD;
&#xD;
      Cycle 1 is 21 days. Treatment repeats every 28 days for cycles 2-9 in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      TAGRAXOFUSP AND MAINTENANCE PHASE:&#xD;
&#xD;
      CYCLES 1-3, 5-7, 9-11, 13-15: Patients receive mercaptopurine PO three time daily (TID) on&#xD;
      days 1-28, prednisone PO once daily (QD) on day 1-5, methotrexate PO once every week (QW) and&#xD;
      vincristine IV over 15 minutes every 4 weeks.&#xD;
&#xD;
      CYCLES 4, 8, and 12: Patients receive tagraxofusp-erzs IV over 15 minutes on days 1-5.&#xD;
&#xD;
      Treatment repeats every 28 days for 15 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then every 3&#xD;
      months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 28, 2022</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Within 3 cycles of treatment initiation: At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Within 3 cycles of treatment initiation: At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Will be monitored simultaneously using the Bayesian approach. Will be estimated along with 95% credible intervals. Chi-square tests or Fisher's exact test will be used to evaluate the association between patient's prognostic factor and response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>Within 3 cycles of treatment initiation: At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Will be estimated along with 95% credible intervals. Chi-square tests or Fisher's exact test will be used to evaluate the association between patient's prognostic factor and response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapsed-free survival (RFS)</measure>
    <time_frame>From the of response to relapsed or death, whichever happens earlier, assessed up to 3 years</time_frame>
    <description>Kaplan-Meier method will be used to estimate the RFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Kaplan-Meier method will be used to estimate the overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related grade 3/4/5 adverse events</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent B Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent T Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory B Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory Lymphoblastic Lymphoma</condition>
  <condition>Refractory T Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Dxevo</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hemady</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim-sndz</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>Filgrastim Biosimilar Filgrastim-sndz</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>3H-Purine-6-thiol</other_name>
    <other_name>6 MP</other_name>
    <other_name>6 Thiohypoxanthine</other_name>
    <other_name>6 Thiopurine</other_name>
    <other_name>6-Mercaptopurine</other_name>
    <other_name>6-Mercaptopurine Monohydrate</other_name>
    <other_name>6-MP</other_name>
    <other_name>6-Purinethiol</other_name>
    <other_name>6-Thiopurine</other_name>
    <other_name>6-Thioxopurine</other_name>
    <other_name>6H-Purine-6-thione, 1,7-dihydro- (9CI)</other_name>
    <other_name>7-Mercapto-1,3,4,6-tetrazaindene</other_name>
    <other_name>Alti-Mercaptopurine</other_name>
    <other_name>Azathiopurine</other_name>
    <other_name>Bw 57-323H</other_name>
    <other_name>Flocofil</other_name>
    <other_name>Ismipur</other_name>
    <other_name>Leukerin</other_name>
    <other_name>Leupurin</other_name>
    <other_name>Mercaleukim</other_name>
    <other_name>Mercaleukin</other_name>
    <other_name>Mercaptina</other_name>
    <other_name>Mercaptopurinum</other_name>
    <other_name>Mercapurin</other_name>
    <other_name>Mern</other_name>
    <other_name>NCI-C04886</other_name>
    <other_name>Puri-Nethol</other_name>
    <other_name>Purimethol</other_name>
    <other_name>Purine, 6-mercapto-</other_name>
    <other_name>Purine-6-thiol (8CI)</other_name>
    <other_name>Purine-6-thiol, monohydrate</other_name>
    <other_name>Purinethiol</other_name>
    <other_name>Purinethol</other_name>
    <other_name>U-4748</other_name>
    <other_name>WR-2785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Give IV</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>2-Mercaptoethanesulfonate, Sodium Salt</other_name>
    <other_name>Ausobronc</other_name>
    <other_name>D-7093</other_name>
    <other_name>Filesna</other_name>
    <other_name>Mercaptoethane Sulfonate</other_name>
    <other_name>Mercaptoethanesulfonate</other_name>
    <other_name>Mesnex</other_name>
    <other_name>Mesnil</other_name>
    <other_name>Mesnum</other_name>
    <other_name>Mexan</other_name>
    <other_name>Mistabron</other_name>
    <other_name>Mistabronco</other_name>
    <other_name>Mitexan</other_name>
    <other_name>Mucofluid</other_name>
    <other_name>Mucolene</other_name>
    <other_name>UCB 3983</other_name>
    <other_name>Uromitexan</other_name>
    <other_name>Ziken</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>filgrastim-SD/01</other_name>
    <other_name>Fulphila</other_name>
    <other_name>HSP-130</other_name>
    <other_name>Jinyouli</other_name>
    <other_name>Neulasta</other_name>
    <other_name>Neulastim</other_name>
    <other_name>Nyvepria</other_name>
    <other_name>Pegcyte</other_name>
    <other_name>Pegfilgrastim Biosimilar HSP-130</other_name>
    <other_name>Pegfilgrastim Biosimilar Nyvepria</other_name>
    <other_name>Pegfilgrastim Biosimilar Pegcyte</other_name>
    <other_name>Pegfilgrastim Biosimilar Udenyca</other_name>
    <other_name>Pegfilgrastim Biosimilar Ziextenzo</other_name>
    <other_name>pegfilgrastim-apgf</other_name>
    <other_name>pegfilgrastim-bmez</other_name>
    <other_name>pegfilgrastim-cbqv</other_name>
    <other_name>Pegfilgrastim-jmdb</other_name>
    <other_name>SD-01</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
    <other_name>Udenyca</other_name>
    <other_name>Ziextenzo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>Rituximab Biosimilar SIBP-02</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tagraxofusp-erzs</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>Diphtheria Toxin(388)-Interleukin-3 Fusion Protein</other_name>
    <other_name>DT(388)-IL3 Fusion Protein</other_name>
    <other_name>DT388IL3 fusion protein</other_name>
    <other_name>Elzonris</other_name>
    <other_name>IL3R-targeting Fusion Protein SL-401</other_name>
    <other_name>SL-401</other_name>
    <other_name>Tagraxofusp</other_name>
    <other_name>Tagraxofusp ERZS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tagraxofusp, chemotherapy)</arm_group_label>
    <other_name>Leurocristine</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincrystine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18-70 years of age with relapsed/refractory CD123+ B- or T-cell acute&#xD;
             lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. CD123 positivity may be&#xD;
             confirmed by either flow cytometry or immunohistochemistry&#xD;
&#xD;
          -  Performance status =&lt; 2 (Eastern Cooperative Oncology Group [ECOG] scale)&#xD;
&#xD;
          -  Total serum bilirubin =&lt; 1.5 x upper limit of normal (ULN), unless due to Gilbert's&#xD;
             syndrome, in which case patients are eligible as long as direct bilirubin =&lt; 2 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) =&lt; 2.5 x ULN, unless due to disease involvement of the&#xD;
             liver or hemolysis, in which case an ALT =&lt; 10 x ULN is acceptable&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) =&lt; 2.5 x ULN, unless due to disease involvement of&#xD;
             the liver or hemolysis, in which case an ALT =&lt; 10 x ULN is acceptable&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  Serum albumin &gt;= 3.2 g/dL (32 g/L). Albumin infusions are not permitted in order to&#xD;
             enable eligibility&#xD;
&#xD;
          -  For females of childbearing potential, a negative pregnancy test must be documented&#xD;
             within 1 week of starting treatment&#xD;
&#xD;
          -  Female and male patients who are fertile must agree to use an effective form of&#xD;
             contraception (birth control methods while on study, such as birth control pills or&#xD;
             injections, intrauterine devices (IUDs), or double-barrier methods (for example, a&#xD;
             condom in combination with spermicide) with their sexual partners for 4 months after&#xD;
             the end of treatment&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Willingness and ability to adhere to study visit schedule and other protocol&#xD;
             requirements, including follow-up for survival assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active serious infection not controlled by oral or intravenous antibiotics&#xD;
&#xD;
          -  Known active central nervous system (CNS) leukemia&#xD;
&#xD;
          -  Diagnosis of Philadelphia chromosome-positive ALL or Burkitt leukemia/lymphoma&#xD;
&#xD;
          -  Active graft versus host disease (GVHD)&#xD;
&#xD;
          -  Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or&#xD;
             squamous cell carcinoma) that in the investigator's opinion will shorten survival to&#xD;
             less than 1 year&#xD;
&#xD;
          -  Known hepatitis B or C infection, or known seropositivity for human immunodeficiency&#xD;
             virus (HIV)&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (e.g., uncontrolled or any New York&#xD;
             Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history&#xD;
             of myocardial infarction, unstable angina or stroke within 6 months prior to study&#xD;
             entry, uncontrolled hypertension or clinically significant arrhythmias not controlled&#xD;
             by medication)&#xD;
&#xD;
          -  Patients with a cardiac ejection fraction (as measured by either multigated&#xD;
             acquisition [MUGA] or echocardiogram) less than the lower limit of normal&#xD;
&#xD;
          -  No clinically significant abnormalities on 12-lead electrocardiogram&#xD;
&#xD;
          -  Uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive&#xD;
             pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator&#xD;
             would put the patient at significant risk for pulmonary complications during the study&#xD;
&#xD;
          -  Persistent clinically significant toxicities grade &gt;= 2 from previous chemotherapy&#xD;
             (excluding alopecia, nausea, fatigue, and liver function tests [as mandated in the&#xD;
             inclusion criteria])&#xD;
&#xD;
          -  Treatment with any investigational antileukemic agents or chemotherapy agents in the&#xD;
             last 7 days before study entry, unless full recovery from side effects has occurred or&#xD;
             patient has rapidly progressive disease judged to be life-threatening by the&#xD;
             investigator. Exception: Treatment with hydroxyurea and/or dexamethasone are allowed&#xD;
             prior to study treatment, without window of exclusion&#xD;
&#xD;
          -  Pregnant and lactating women will not be eligible; women of childbearing potential&#xD;
             should have a negative pregnancy test prior to entering on the study and be willing to&#xD;
             practice methods of contraception for 4 months after last study treatment. Women do&#xD;
             not have childbearing potential if they have had a hysterectomy or are postmenopausal&#xD;
             without menses for 12 months. In addition, men enrolled on this study should&#xD;
             understand the risks to any sexual partner of childbearing potential and should&#xD;
             practice an effective method of birth control for 4 months after last study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Short</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicholas Short</last_name>
      <phone>713-563-4485</phone>
      <email>nshort@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Nicholas Short</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

